⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22745675 | 0.77 | — | — | |
| SCHEMBL9254727 | 0.77 | — | — | |
| SCHEMBL11742328 | 0.77 | — | — | |
| SCHEMBL11744009 | 0.77 | — | — | |
| SCHEMBL11458680 | 0.76 | — | — | |
| SCHEMBL15476585 | 0.74 | — | — | |
| SCHEMBL5423123 | 0.71 | — | — | |
| SCHEMBL2080226 | 0.71 | — | — | |
| SCHEMBL261788 | 0.71 | — | — | |
| SCHEMBL11746606 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180335-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | Angion Biomedica Corporation (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2016025424-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORPORATION (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2793893-A2 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | Intellikine, LLC (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2776837-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | Intellikine, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776441-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | Intellikine, LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014093960-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2705181-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Intellikine, LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2014015137-A2 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | ANGION BIOMEDICA CORP. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2013085824-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2006012422-A1 | IMIDAZOPYRAZINE AS TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005007631-A1 | NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002079176-A1 | PROCESS FOR 2,4-DISUBSTITUTED-1,3,4-OXADIAZOLINE-5-THIONE AND 5-ONE COMPOUNDS | DOW AGROSCIENCES LLC (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |